Raman Sankar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10820353/publications.pdf

Version: 2024-02-01

		36203	40881
179	9,607	51	93
papers	citations	h-index	g-index
188	188	188	7742
100	100	100	7742
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Pathophysiological Mechanisms of Brain Damage from Status Epilepticus. Epilepsia, 1993, 34, S37-53.	2.6	425
2	Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy. New England Journal of Medicine, 2017, 377, 1630-1638.	13.9	412
3	Patterns of Status Epilepticus-Induced Neuronal Injury during Development and Long-Term Consequences. Journal of Neuroscience, 1998, 18, 8382-8393.	1.7	389
4	Assessment and surgical outcomes for mild type I and severe type II cortical dysplasia: A critical review and the UCLA experience. Epilepsia, 2009, 50, 1310-1335.	2.6	345
5	Childhood absence epilepsy: Behavioral, cognitive, and linguistic comorbidities. Epilepsia, 2008, 49, 1838-1846.	2.6	313
6	Surgery for Intractable Infantile Spasms: Neuroimaging Perspectives. Epilepsia, 1993, 34, 764-771.	2.6	275
7	The mechanism of action of retigabine (ezogabine), a firstâ€inâ€class K ⁺ channel opener for the treatment of epilepsy. Epilepsia, 2012, 53, 412-424.	2.6	261
8	Infantile spasms: II. Lenticular nuceli and brain stem activation on positron emission tomography. Annals of Neurology, 1992, 31, 212-219.	2.8	259
9	Time-dependent decrease in the effectiveness of antiepileptic drugs during the course of self-sustaining status epilepticus. Brain Research, 1998, 814, 179-185.	1.1	227
10	Modulation of Hippocampal Excitability and Seizures by Galanin. Journal of Neuroscience, 2000, 20, 6276-6281.	1.7	206
11	Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox–Gastaut syndrome. Epilepsy and Behavior, 2015, 47, 138-141.	0.9	189
12	Hemispherectomy for intractable seizures in children: a report of 58 cases. Child's Nervous System, 1996, 12, 376-384.	0.6	174
13	Galanin Modulation of Seizures and Seizure Modulation of Hippocampal Galanin in Animal Models of Status Epilepticus. Journal of Neuroscience, 1998, 18, 10070-10077.	1.7	172
14	Depression after status epilepticus: behavioural and biochemical deficits and effects of fluoxetine. Brain, 2008, 131, 2071-2083.	3.7	170
15	The Pharmacologic Basis of Antiepileptic Drug Action. Epilepsia, 1999, 40, 1471-1483.	2.6	162
16	Children with ESES: Variability in the Syndrome. Epilepsy Research, 2006, 70, 248-258.	0.8	151
17	Developmental outcomes in children receiving resection surgery for medically intractable infantile spasms. Developmental Medicine and Child Neurology, 1997, 39, 430-440.	1.1	148
18	Epileptogenesis after status epilepticus reflects age- and model-dependent plasticity. Annals of Neurology, 2000, 48, 580-589.	2.8	130

#	Article	IF	CITATIONS
19	Elevated plasma corticosterone level and depressive behavior in experimental temporal lobe epilepsy. Neurobiology of Disease, 2009, 34, 457-461.	2.1	130
20	Inflammation induced by LPS enhances epileptogenesis in immature rat and may be partially reversed by IL1RA. Epilepsia, 2010, 51, 34-38.	2.6	128
21	Measures of Psychopathology in Children With Complex Partial Seizures and Primary Generalized Epilepsy With Absence. Journal of the American Academy of Child and Adolescent Psychiatry, 2001, 40, 907-914.	0.3	121
22	Psychopathology and Pediatric Complex Partial Seizures: Seizure-related, Cognitive, and Linguistic Variables. Epilepsia, 2004, 45, 1273-1281.	2.6	115
23	Energy-dependent volume regulation in primary cultured cerebral astrocytes. Journal of Cellular Physiology, 1986, 128, 209-215.	2.0	108
24	Self-sustaining status epilepticus after brief electrical stimulation of the perforant path. Brain Research, 1998, 801, 251-253.	1.1	104
25	GABAA Receptor Physiology and Its Relationship to the Mechanism of Action of the 1,5-Benzodiazepine Clobazam. CNS Drugs, 2012, 26, 229-244.	2.7	101
26	Comorbidity between epilepsy and depression: Role of hippocampal interleukin- $1\hat{l}^2$. Neurobiology of Disease, 2010, 37, 461-467.	2.1	99
27	Serum neuron-specific enolase is a marker for neuronal damage following status epilepticus in the rat. Epilepsy Research, 1997, 28, 129-136.	0.8	97
28	Frontal and temporal volumes in Childhood Absence Epilepsy. Epilepsia, 2009, 50, 2466-2472.	2.6	96
29	Hypsarrhythmia assessment exhibits poor interrater reliability: A threat to clinical trial validity. Epilepsia, 2015, 56, 77-81.	2.6	93
30	Granule Cell Neurogenesis After Status Epilepticus in the Immature Rat Brain. Epilepsia, 2000, 41, S53-S56.	2.6	90
31	Regulation of Kindling Epileptogenesis by Hippocampal Galanin Type 1 and Type 2 Receptors: The Effects of Subtype-Selective Agonists and the Role of G-Protein-Mediated Signaling. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 700-708.	1.3	88
32	Neonatal seizures. Neurology, 2005, 64, 776-777.	1.5	85
33	Insulin-responsive glucose transporters—GLUT8 and GLUT4 are expressed in the developing mammalian brain. Molecular Brain Research, 2002, 107, 157-165.	2.5	83
34	Treatment of Experimental Status Epilepticus in Immature Rats: Dissociation Between Anticonvulsant and Antiepileptogenic Effects. Pediatric Research, 2006, 59, 237-243.	1.1	81
35	Kindling epileptogenesis in immature rats leads to persistent depressive behavior. Epilepsy and Behavior, 2007, 10, 377-383.	0.9	81
36	Interleukin-1beta Causes Fluoxetine Resistance in an Animal Model of Epilepsy-Associated Depression. Neurotherapeutics, 2012, 9, 477-485.	2.1	80

#	Article	IF	Citations
37	Inflammation Exacerbates Seizureâ€induced Injury in the Immature Brain. Epilepsia, 2007, 48, 27-34.	2.6	79
38	Comorbidity between epilepsy and depression: Experimental evidence for the involvement of serotonergic, glucocorticoid, and neuroinflammatory mechanisms. Epilepsia, 2010, 51, 110-114.	2.6	79
39	Maternal immune activation promotes hippocampal kindling epileptogenesis in mice. Annals of Neurology, 2013, 74, 11-19.	2.8	79
40	Inflammation enhances epileptogenesis in the developing rat brain. Neurobiology of Disease, 2010, 40, 303-310.	2.1	78
41	Bumetanide inhibits rapid kindling in neonatal rats. Epilepsia, 2009, 50, 2117-2122.	2.6	77
42	Neuroprotective and antiepileptogenic effects of combination of anti-inflammatory drugs in the immature brain. Journal of Neuroinflammation, 2013, 10, 30.	3.1	74
43	Social competence in pediatric epilepsy: insights into underlying mechanisms. Epilepsy and Behavior, 2005, 6, 218-228.	0.9	73
44	Possible precision medicine implications from genetic testing using combined detection of sequence and intragenic copy number variants in a large cohort with childhood epilepsy. Epilepsia Open, 2019, 4, 397-408.	1.3	68
45	Language in pediatric epilepsy. Epilepsia, 2009, 50, 2397-2407.	2.6	67
46	Facilitation of kindling epileptogenesis by chronic stress may be mediated by intestinal microbiome. Epilepsia Open, 2018, 3, 290-294.	1.3	66
47	Treatment of infantile spasms with very high dose prednisolone before high dose adrenocorticotropic hormone. Epilepsia, 2014, 55, 103-107.	2.6	65
48	Seizure-induced neuronal death in the immature brain. Progress in Brain Research, 2002, 135, 335-353.	0.9	63
49	Neurocognitive profiles in children with epilepsy. Epilepsia, 2012, 53, 2156-2163.	2.6	62
50	The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: Implications for clinical use. Epilepsia, 2012, 53, 425-436.	2.6	60
51	In vivo interaction between serotonin and galanin receptors types 1 and 2 in the dorsal raphe: implication for limbic seizures. Journal of Neurochemistry, 2005, 95, 1495-1503.	2.1	56
52	Induction of brain derived neurotrophic factor mRNA by seizures in neonatal and juvenile rat brain. Molecular Brain Research, 1997, 44, 219-228.	2.5	55
53	Paroxysmal fast activity: An interictal scalp EEG marker of epileptogenesis in children. Epilepsy Research, 2008, 82, 99-106.	0.8	54
54	Risk of vigabatrinâ€associated brain abnormalities on <scp>MRI</scp> in the treatment of infantile spasms is doseâ€dependent. Epilepsia, 2017, 58, 674-682.	2.6	53

#	Article	IF	Citations
55	Behavioral impairments in rats with chronic epilepsy suggest comorbidity between epilepsy and attention deficit/hyperactivity disorder. Epilepsy and Behavior, 2014, 31, 267-275.	0.9	51
56	Self-Sustaining Status Epilepticus: A Condition Maintained by Potentiation of Glutamate Receptors and by Plastic Changes in Substance P and Other Peptide Neuromodulators. Epilepsia, 2000, 41, S134-S143.	2.6	50
57	Postnatal hypoxic-ischemic brain injury alters mechanisms mediating neuronal glucose transport. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2004, 286, R273-R282.	0.9	50
58	Epileptogenesis After Self-Sustaining Status Epilepticus. Epilepsia, 2002, 43, 74-80.	2.6	49
59	Anticonvulsant effects of the selective melatonin receptor agonist ramelteon. Epilepsy and Behavior, 2009, 16, 52-57.	0.9	49
60	The Ketogenic Diet as Broad-Spectrum Treatment for Super-Refractory Pediatric Status Epilepticus. Journal of Child Neurology, 2015, 30, 259-266.	0.7	49
61	Short-Term Plasticity of Hippocampal Neuropeptides and Neuronal Circuitry in Experimental Status Epilepticus. Epilepsia, 2002, 43, 20-29.	2.6	47
62	Amantadine: A new treatment for refractory electrical status epilepticus in sleep. Epilepsy and Behavior, 2018, 84, 74-78.	0.9	47
63	Visual and semi-automatic non-invasive detection of interictal fast ripples: A potential biomarker of epilepsy in children with tuberous sclerosis complex. Clinical Neurophysiology, 2018, 129, 1458-1466.	0.7	46
64	Time to pediatric epilepsy surgery is related to disease severity and nonclinical factors. Neurology, 2013, 80, 1231-1239.	1.5	45
65	Thought disorder: A developmental disability in pediatric epilepsy. Epilepsy and Behavior, 2006, 8, 726-735.	0.9	43
66	Suicidality and brain volumes in pediatric epilepsy. Epilepsy and Behavior, 2010, 18, 286-290.	0.9	42
67	Do Seizures Affect the Developing Brain? Lessons From the Laboratory. Journal of Child Neurology, 2007, 22, 21S-29S.	0.7	41
68	A comparison of levetiracetam and phenobarbital for the treatment of neonatal seizures associated with hypoxic–ischemic encephalopathy. Epilepsy and Behavior, 2018, 88, 212-217.	0.9	40
69	Immunohistochemical study of p53-associated proteins in rat brain following lithium–pilocarpine status epilepticus. Brain Research, 2002, 929, 129-138.	1.1	39
70	Antiepileptogenic and antiictogenic effects of retigabine under conditions of rapid kindling: An ontogenic study. Epilepsia, 2008, 49, 1777-1786.	2.6	39
71	Plasticity of Presynaptic and Postsynaptic Serotonin 1A Receptors in an Animal Model of Epilepsy-Associated Depression. Neuropsychopharmacology, 2011, 36, 1305-1316.	2.8	39
72	WONOEP appraisal: Biomarkers of epilepsyâ€associated comorbidities. Epilepsia, 2017, 58, 331-342.	2.6	39

#	Article	IF	CITATIONS
73	Reduced Anesthetization during the Intracarotid Amobarbital (Wada) Test in Patients Taking Carbonic Anhydrase-Inhibiting Medications. Epilepsia, 2005, 46, 236-243.	2.6	37
74	Status Epilepticus Triggers Caspase-3 Activation and Necrosis in the Immature Rat Brain. Epilepsia, 2007, 48, 1203-1206.	2.6	37
75	Recognition of Infantile Spasms Is Often Delayed: The ASSIST Study. Journal of Pediatrics, 2017, 190, 215-221.e1.	0.9	36
76	Dealing with epilepsy: Parents speak up. Epilepsy and Behavior, 2008, 13, 131-138.	0.9	35
77	Effects of selective serotonin and norepinephrine reuptake inhibitors on depressiveâ€and impulsiveâ€like behaviors and on monoamine transmission in experimental temporal lobe epilepsy. Epilepsia, 2016, 57, 506-515.	2.6	33
78	Common Mechanisms Underlying Epileptogenesis and the Comorbidities of Epilepsy. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a022798.	2.9	33
79	Initial treatment of epilepsy with antiepileptic drugs. Neurology, 2004, 63, S30-9.	1.5	33
80	Treatment Strategies for Myoclonic Seizures and Epilepsy Syndromes with Myoclonic Seizures. Epilepsia, 2003, 44, 27-37.	2.6	32
81	Visual Field Defects and Other Ophthalmological Disturbances Associated with Vigabatrin. Drug Safety, 2001, 24, 385-404.	1.4	31
82	Scalp EEG interictal high frequency oscillations as an objective biomarker of infantile spasms. Clinical Neurophysiology, 2020, 131, 2527-2536.	0.7	31
83	GABA metabolism during status epilepticus in the developing rat brain. Developmental Brain Research, 1997, 98, 60-64.	2.1	30
84	Differential induction of p53 in immature and adult rat brain following lithium–pilocarpine status epilepticus. Brain Research, 2002, 928, 187-193.	1.1	30
85	Status Epilepticus and Frequent Seizures: Incidence and Clinical Characteristics in Pediatric Epilepsy Surgery Patients. Epilepsia, 2005, 46, 1950-1954.	2.6	30
86	Pediatric Epilepsy Surgery. Neurosurgery, 2012, 71, 985-993.	0.6	30
87	Evaluation of developmentâ€specific targets for antiepileptogenic therapy using rapid kindling. Epilepsia, 2010, 51, 39-42.	2.6	28
88	Mechanisms of Action for the Commonly Used Antiepileptic Drugs: Relevance to Antiepileptic Drug-Associated Neurobehavioral Adverse Effects. Journal of Child Neurology, 2004, 19, S6-S14.	0.7	27
89	Intraoperative fast ripples independently predict postsurgical epilepsy outcome: Comparison with other electrocorticographic phenomena. Epilepsy Research, 2017, 135, 79-86.	0.8	27
90	Hypoxicâ€ischemic brain injury exacerbates neuronal apoptosis and precipitates spontaneous seizures in glucose transporter isoform 3 heterozygous null mice. Journal of Neuroscience Research, 2010, 88, 3386-3398.	1.3	26

#	Article	IF	CITATIONS
91	Prospective observational study: Fast ripple localization delineates the epileptogenic zone. Clinical Neurophysiology, 2019, 130, 2144-2152.	0.7	26
92	Unmet mental health needs in pediatric epilepsy: Insights from providers. Epilepsy and Behavior, 2007, 11, 401-408.	0.9	25
93	Is the devil we know the lesser of two evils?. Neurology, 1999, 52, 1537-1537.	1.5	24
94	Epileptogenesis During Development: Injury, Circuit Recruitment, and Plasticity. Epilepsia, 2002, 43, 47-53.	2.6	23
95	Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms. Neuropsychiatric Disease and Treatment, 2010, 6, 731.	1.0	23
96	Time to Pediatric Epilepsy Surgery Is Longer and Developmental Outcomes Lower for Government Compared With Private Insurance. Neurosurgery, 2013, 73, 152-157.	0.6	23
97	Disruption of intestinal barrier and endotoxemia after traumatic brain injury: Implications for postâ€traumatic epilepsy. Epilepsia, 2021, 62, 1472-1481.	2.6	23
98	Age-dependent Effects of Topiramate on the Acquisition and the Retention of Rapid Kindling. Epilepsia, 2007, 48, 765-773.	2.6	22
99	Prospective and "live―fast ripple detection and localization in the operating room: Impact on epilepsy surgery outcomes in children. Epilepsy Research, 2016, 127, 344-351.	0.8	21
100	Interrater reliability in visual identification of interictal highâ€frequency oscillations on electrocorticography and scalp <scp>EEG</scp> . Epilepsia Open, 2018, 3, 127-132.	1.3	21
101	Synthetic pharmaceutical grade cannabidiol for treatment of refractory infantile spasms: A multicenter phase-2 study. Epilepsy and Behavior, 2020, 102, 106826.	0.9	21
102	Amygdala volume and psychopathology in childhood complex partial seizures. Epilepsy and Behavior, 2008, 13, 212-217.	0.9	20
103	A lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: The UCLA experience. Epilepsy and Behavior, 2016, 57, 29-33.	0.9	20
104	Kindling epileptogenesis and panic-like behavior: Their bidirectional connection and contribution to epilepsy-associated depression. Epilepsy and Behavior, 2017, 77, 33-38.	0.9	20
105	Sex-Specific Life Course Changes in the Neuro-Metabolic Phenotype of Glut3 Null Heterozygous Mice: Ketogenic Diet Ameliorates Electroencephalographic Seizures and Improves Sociability. Endocrinology, 2017, 158, 936-949.	1.4	20
106	Prevention of infantile spasms relapse: Zonisamide and topiramate provide no benefit. Epilepsia, 2016, 57, 1280-1287.	2.6	19
107	Interictal scalp fast ripple occurrence and high frequency oscillation slow wave coupling in epileptic spasms. Clinical Neurophysiology, 2020, 131, 1433-1443.	0.7	18
108	Ontogeny of Self-Sustaining Status epilepticus. Developmental Neuroscience, 1999, 21, 345-351.	1.0	17

#	Article	IF	Citations
109	Limited efficacy of the ketogenic diet in the treatment of highly refractory epileptic spasms. Seizure: the Journal of the British Epilepsy Association, 2016, 35, 59-64.	0.9	17
110	Frontal and temporal volumes in children with epilepsy. Epilepsy and Behavior, 2007, 10, 470-476.	0.9	16
111	Obstacles to mental health care in pediatric epilepsy: Insight from parents. Epilepsy and Behavior, 2009, 14, 360-366.	0.9	16
112	Melanotan-II reverses autistic features in a maternal immune activation mouse model of autism. PLoS ONE, 2019, 14, e0210389.	1.1	16
113	Thought disorder and frontotemporal volumes in pediatric epilepsy. Epilepsy and Behavior, 2008, 13, 593-599.	0.9	15
114	Deconstructing tolerance with clobazam. Neurology, 2016, 87, 1806-1812.	1.5	15
115	Inherent vulnerabilities in monoaminergic pathways predict the emergence of depressive impairments in an animal model of chronic epilepsy. Epilepsia, 2017, 58, e116-e121.	2.6	15
116	Octanoic Acid Inhibits Astrocyte Volume Control: Implications for Cerebral Edema in Reye's Syndrome. Journal of Neurochemistry, 1989, 52, 1197-1202.	2.1	14
117	Language and brain volumes in children with epilepsy. Epilepsy and Behavior, 2010, 17, 402-407.	0.9	14
118	Cytokine-dependent bidirectional connection between impaired social behavior and susceptibility to seizures associated with maternal immune activation in mice. Epilepsy and Behavior, 2015, 50, 40-45.	0.9	14
119	Galanin contributes to monoaminergic dysfunction and to dependent neurobehavioral comorbidities of epilepsy. Experimental Neurology, 2017, 289, 64-72.	2.0	14
120	Very-High-Dose Prednisolone Before ACTH for Treatment of Infantile Spasms: Evaluation of a Standardized Protocol. Pediatric Neurology, 2019, 99, 16-22.	1.0	14
121	Refining epileptogenic high-frequency oscillations using deep learning: a reverse engineering approach. Brain Communications, 2022, 4, fcab267.	1.5	14
122	Vigabatrin. Seminars in Pediatric Neurology, 1997, 4, 43-50.	1.0	13
123	A multicenter, outpatient, open-label study to evaluate the dosing, effectiveness, and safety of topiramate as monotherapy in the treatment of epilepsy in clinical practice. Epilepsy and Behavior, 2009, 15, 506-512.	0.9	13
124	Neurobiology of depression as a comorbidity of epilepsy. Epilepsia, 2010, 51, 81-81.	2.6	13
125	Autism-Like Behavior in BTBR Mice Is Improved by Electroconvulsive Therapy. Neurotherapeutics, 2015, 12, 657-666.	2.1	13
126	Susceptibility to epilepsy after traumatic brain injury is associated with preexistent gut microbiome profile. Epilepsia, 2022, 63, 1835-1848.	2.6	13

#	Article	IF	Citations
127	Understanding Therapeutic Equivalence in Epilepsy. CNS Spectrums, 2010, 15, 112-123.	0.7	12
128	Successful use of pure cannabidiol for the treatment of super-refractory status epilepticus. Epilepsy & Behavior Case Reports, 2018, 10, 141-144.	1.5	12
129	Hippocampal volume in childhood complex partial seizures. Epilepsy Research, 2006, 72, 57-66.	0.8	10
130	Sociodemographic changes over 25 years of pediatric epilepsy surgery at UCLA. Journal of Neurosurgery: Pediatrics, 2013, 11, 250-255.	0.8	10
131	Potential induction of epileptic spasms by nonselective voltage-gated sodium channel blockade: Interaction with etiology. Epilepsy and Behavior, 2021, 115, 107624.	0.9	10
132	Pharmacologic Treatment of Intractable Epilepsy in Children: A Syndrome-Based Approach. Seminars in Pediatric Neurology, 2011, 18, 171-178.	1.0	9
133	Clinical considerations in transitioning patients with epilepsy from clonazepam to clobazam: a case series. Journal of Medical Case Reports, 2014, 8, 429.	0.4	9
134	Epileptogenesis after status epilepticus reflects age- and model-dependent plasticity., 2000, 48, 580.		9
135	Age-Dependent Differences in Flurothyl-Induced c-fos and c-jun mRNA Expression in the Mouse Brain. Developmental Neuroscience, 2002, 24, 294-299.	1.0	8
136	Animal Model of Cortical Dysplasia for Screening Candidate AEDs. Epilepsy Currents, 2003, 3, 6-7.	0.4	8
137	The Utility of Testing Pentylenetetrazol Threshold. Epilepsia, 2006, 47, 662-663.	2.6	8
138	Status Epilepticus: Electrical Stimulation Models. , 2006, , 449-464.		8
139	Early Infantile Epileptic Encephalopathy with a de novo variant in ZEB2 identified by exome sequencing. European Journal of Medical Genetics, 2016, 59, 70-74.	0.7	8
140	Limited efficacy of zonisamide in the treatment of refractory infantile spasms. Epilepsia Open, 2020, 5, 121-126.	1.3	8
141	Chapter 12 Teratogenicity of Antiepileptic Drugs. International Review of Neurobiology, 2008, 83, 215-225.	0.9	7
142	Felbamate in the treatment of refractory epileptic spasms. Epilepsy Research, 2020, 161, 106284.	0.8	7
143	Neuroprotection in epilepsy: The Holy Grail of antiepileptogenic therapy. Epilepsy and Behavior, 2005, 7, 1-2.	0.9	6
144	Value of genetic testing for pediatric epilepsy: Driving earlier diagnosis of ceroid lipofuscinosis type 2 Batten disease. Epilepsia, 2022, 63, .	2.6	6

#	Article	IF	CITATIONS
145	Inflammation modifies status epilepticusâ€induced hippocampal injury during development. Epilepsia, 2007, 48, 16-18.	2.6	5
146	Regulation of kindling epileptogenesis by hippocampal Tollâ€like receptors 2. Epilepsia, 2017, 58, e122-e126.	2.6	4
147	Hypothalamic Hamartoma With Infantile Spasms: Case Report With Surgical Treatment. Seminars in Pediatric Neurology, 2018, 26, 115-118.	1.0	4
148	Knowledge gaps for functional outcomes after multilobar resective and disconnective pediatric epilepsy surgery: Conference Proceedings of the Patientâ€Centered Stakeholder Meeting 2019. Epileptic Disorders, 2022, 24, 50-66.	0.7	4
149	Status Epilepticus: Danse Macabre in a Ballet of Subunits. Epilepsy Currents, 2006, 6, 102-105.	0.4	2
150	Long-term safety and tolerability of adjunctive eslicarbazepine acetate in children with focal seizures. Epilepsy and Behavior, 2020, 112, 107458.	0.9	2
151	Pharmacotherapy for Medication-Resistant Epilepsy. , 2020, , 179-186.		2
152	Diversity of kindling of limbic seizures after lateral fluid percussion injury in the rat. Epilepsia Open, 2021, 6, 413-418.	1.3	2
153	Development of Temporal Lobe Epilepsy in 21-day-old Rats. Epilepsia, 2003, 44, 872-872.	2.6	1
154	Galanin and Epilepsy: Promises with Nuances …. Epilepsy Currents, 2005, 5, 78-80.	0.4	1
155	Does adjunctive lamotrigine provide improved control of primary generalized tonic–clonic seizures in children?. Nature Clinical Practice Neurology, 2007, 3, 306-307.	2.7	1
156	Medication-Resistant Epilepsy in Adults. , 2020, , 158-170.		1
157	Environmental Factors Influence Neurogenesis and Modify the Cognitive Outcome after Status Epilepticus. Epilepsy Currents, 2003, 3, 8-10.	0.4	0
158	Levetiracetam: its use in partial-onset seizure. Expert Review of Neurotherapeutics, 2003, 3, 751-760.	1.4	0
159	The Natural History of Epilepsy. , 2020, , 1-13.		0
160	Challenges in Identifying Medication-Resistant Epilepsy. , 2020, , 14-19.		0
161	International League Against Epilepsy's Definition of Medication-Resistant Epilepsy. , 2020, , 20-26.		0
162	The Economic Impact of Medication-Resistant Epilepsy. , 2020, , 27-33.		0

#	Article	IF	CITATIONS
163	Social Consequences of Medication-Resistant Epilepsy. , 2020, , 34-38.		O
164	Mortality and Morbidity of Medication-Resistant Epilepsy. , 2020, , 39-50.		0
165	Models for Medication-Resistant Epilepsy. , 2020, , 51-61.		O
166	Neurobiology of Medication-Resistant Epilepsy. , 2020, , 62-68.		0
167	Genetic Causes of Medication-Resistant Epilepsy. , 2020, , 69-78.		O
168	Malformations of Cortical Development as Causes of Medication-Resistant Epilepsy. , 2020, , 79-86.		O
169	Hippocampal Sclerosis as a Cause of Medication-Resistant Epilepsy. , 2020, , 87-99.		O
170	Autoimmune Causes of Medication-Resistant Epilepsy. , 2020, , 100-117.		0
171	Medication-Resistant Epilepsy Syndromes in Children. , 2020, , 118-157.		O
172	Approach to the Treatment of Medication-Resistant Epilepsy. , 2020, , 171-178.		0
173	Reproductive Health for Women with Medication-Resistant Epilepsy. , 2020, , 187-197.		O
174	Resective Surgery for Medication-Resistant Epilepsy., 2020,, 198-209.		O
175	Ablative Surgery for Medication-Resistant Epilepsy. , 2020, , 210-218.		O
176	Stimulation Treatment for Medication-Resistant Epilepsy. , 2020, , 219-240.		O
177	Diet Therapy for Medication-Resistant Epilepsy. , 2020, , 241-247.		O
178	Botanical Treatments for Medication-Resistant Epilepsy. , 2020, , 248-255.		0
179	Psychiatric Comorbidities in Medication-Resistant Epilepsy. , 2020, , 256-268.		O